Shots:

• The company reported the initiation of the P-III (MELODY-1) clinical study to evaluate the safety and efficacy of PL9643 vs vehicle in ~400 patients with dry eye disease at multiple US sites. The study is based on the results from the P-II study
• PL9643 is a second melanocortin peptide that is being evaluated in the P-III study & demonstrate Palatin's expertise and efficiency in melanocortin peptide development
• The results from the (MELODY-1) is expected in H2’22 while MELODY-2 data in H2’23 with an anticipated NDA submission in H1’24

Ref: PR Newswire | Image: Palatin